Inactive Instrument

Keryx Biopharmaceuticals

Equities

US4925151015

Keryx Biopharmaceuticals, Inc. Announces Resignation of Brian Adams as General Counsel and Secretary

February 16, 2018 at 04:31 pm EST

On February 12, 2018, Brian Adams, Keryx Biopharmaceuticals, Inc.’s General Counsel and Secretary and one of the Company’s “named executive officers,” notified the Company that he was resigning his positions with the Company effective as of March 13, 2018 to accept a position at another company.

Latest news about Keryx Biopharmaceuticals

Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc. and Averoa SAS Enter into License Agreement	22-12-28	CI
Keryx Biopharmaceuticals, Inc. Announces Settlement of Auryxia Patent Litigation with Panion & Bf Biotech Inc	19-08-05	CI
Keryx Biopharmaceuticals, Inc., and Panion & BF Biotech, Inc Enters into License Agreement with Par Pharmaceutical, Inc	19-08-05	CI
Keryx Biopharmaceuticals, Inc.(NasdaqCM:KERX) dropped from S&P Biotechnology Select Industry Index	18-12-14	CI
Keryx Biopharmaceuticals, Inc.(NasdaqCM:KERX) dropped from S&P TMI Index	18-12-14	CI
Keryx Biopharmaceuticals, Inc.(NasdaqCM:KERX) dropped from S&P Global BMI Index	18-12-14	CI
Keryx Biopharmaceuticals, Inc. Announces Executive Changes	18-12-13	CI
Keryx Biopharmaceuticals, Inc.(NasdaqGM:KERX) dropped from Russell 2000 Index	18-12-13	CI
Keryx Biopharmaceuticals, Inc.(NasdaqGM:KERX) dropped from Russell 3000 Index	18-12-13	CI
Keryx Biopharmaceuticals, Inc.(NasdaqGM:KERX) dropped from NASDAQ Composite Index	18-12-12	CI
Akebia Therapeutics Inc. (‘Akebia’) completed the acquisition of Keryx Biopharmaceuticals Inc. (‘Keryx’) from Baupost Group Securities LLC (‘Baupost’), Abrams Capital LLC, The Vanguard Group Inc. and other shareholders in a merger of equals transaction.	18-12-11	CI
Keryx Biopharmaceuticals, Inc. and Akebia Therapeutics, Inc. Announce Board Changes	18-11-15	CI
Keryx Biopharmaceuticals, Inc. Reports Unaudited and Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	18-11-07	CI
Transcript : Keryx Biopharmaceuticals, Inc., Q2 2018 Earnings Call, Aug 08, 2018	18-08-08
Keryx Biopharmaceuticals, Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	18-08-08	CI
Transcript : Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc. - M&A Call	18-06-28
Akebia Therapeutics Inc. entered into an agreement acquire Keryx Biopharmaceuticals Inc. from Baupost Group Securities LLC, Abrams Capital LLC, The Vanguard Group Inc. and other shareholders for approximately $480 million in a merger of equals transaction.	18-06-27	CI
Transcript : Keryx Biopharmaceuticals, Inc. Presents at Key Opinion Leader Symposium, May-31-2018 12:00 PM	18-05-31
Transcript : Keryx Biopharmaceuticals, Inc. - Special Call	18-05-25
Transcript : Keryx Biopharmaceuticals, Inc., Q1 2018 Earnings Call, May 10, 2018	18-05-10
Keryx Biopharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	18-05-10	CI
Keryx Biopharmaceuticals, Inc. Announces Management Changes	18-04-30	CI
Keryx Biopharmaceuticals, Inc. Provides Preliminary Revenue Results for the First Quarter 2018	18-04-30	CI
Keryx Biopharmaceuticals, Inc. Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficiency Anemia in Patients with Chronic Kidney Disease, Not on Dialysis, in the American Journal of Hematology	18-04-04	CI
Keryx Biopharmaceuticals, Inc. Announces Resignation of Brian Adams as General Counsel and Secretary	18-02-16	CI

Chart Keryx Biopharmaceuticals

Duration

Period

More charts

Company Profile

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.

Sector

More about the company